NCT00001393 is a clinical trial in Focal Segmental Glomerulosclerosis, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Who is sponsoring NCT00001393?

NCT00001393 is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

What condition does NCT00001393 study?

NCT00001393 studies Focal Segmental Glomerulosclerosis, HIV-Associated Focal Segmental Glomerulosclerosis.

Is NCT00001393 still recruiting?

NCT00001393 is currently completed. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT00001393

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Markers for Focal Segmental Glomerulosclerosis

Completed Last updated 14 April 2026

What this trial tests

trial in Focal Segmental Glomerulosclerosis in 616 participants. Completed.

Timeline

15 April 1996

Quick facts

Lead sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	616
Start date	15 April 1996
Sites	1 location across United States

Conditions studied

Focal Segmental Glomerulosclerosis — all drugs for Focal Segmental Glomerulosclerosis →
HIV-Associated Focal Segmental Glomerulosclerosis — all drugs for HIV-Associated Focal Segmental Glomerulosclerosis →

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who can join

19 Months and older, any sex, with Focal Segmental Glomerulosclerosis or HIV-Associated Focal Segmental Glomerulosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Glomerulonephritis is a disease which affect the kidneys. Occasionally these diseases can progress to a loss of kidney function in some patients. Glomerulosclerosis or focal segmental glomerulosclerosis (FSGS) is one form of glomerulonephritis. The cause of FSGS is unknown and often occurs on its own (idiopathic), or it can be associated with HIV (Human Immunodeficiency Virus). FSGS occurs more commonly among black patients than Caucasian or Hispanic patients. Researchers believe that environmental factors may interact with genetic mutations to cause FSGS, at least in some patients. This study will attempt to identify genetic factors associated with the development of FSGS. The study population will be made up of 600 total subjects divided into 3 groups. Group one will be 200 African-Americans with FSGS. Group two will be 200 African-Americans with HIV but without FSGS. Group three will be 200 non-African-Americans with FSGS. Study participation requires that researchers obtain 20 ml (2 tubes of blood). The genetic material (DNA) will be prepared from the white blood cells and analyzed. The results of each group will be compared with the results from the other groups to determine if one or more genes predisposes to FSGS. In the long run, studies that demonstrate a genetic basis for FSGS may help us identify patients earlier and may lead to improved therapies....

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Focal Segmental Glomerulosclerosis

Currently open trials in the same condition.

NCT06664814 — An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomeruloscleros · Phase 2 · recruiting
NCT07220083 — A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc · Phase 3 · recruiting
NCT06500702 — A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Ye · Phase 2 · recruiting
NCT05942625 — A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects · Phase 1 · recruiting
NCT05588063 — taVNS for FRNS in Children · NA · recruiting

Other National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) trials

Trials by the same sponsor.

NCT07313787 — Effects of Meal Macronutrients on Postprandial Lipids · Phase 2 · not yet recruiting
NCT07388537 — Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults · not yet recruiting
NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
NCT05722210 — Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant · not yet recruiting
NCT07191561 — Hepatic Lipid Metabolism-Alcohol Use Disorder · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00001393 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing